Google
KNSA — KINIKSA PHARMACEUTICALS LTD (Healthcare >> Drug Manufacturers - Specialty & Generic)
KNSA FAQ
What is KNSA's P/E ratio?
KINIKSA PHARMACEUTICALS LTD (KNSA) currently trades at a P/E ratio of 49.41.
What is KNSA's ROE?
KINIKSA PHARMACEUTICALS LTD reports a Return on Equity (ROE) of 12.06%.
What is KNSA's dividend yield?
KINIKSA PHARMACEUTICALS LTD offers a dividend yield of 0.00%.
What is KNSA's Deepscope Quality Score?
Deepscope rates KNSA's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KNSA?
Deepscope's AI Timing Score for KNSA is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KNSA belong to?
KINIKSA PHARMACEUTICALS LTD is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 47.85
Price
0.93
(1.98%)
Day Change
|
|
|---|
KNSA, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROEの伸びが低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1949
|
| Magic Formula Rank by ROE |
1949
|
| Magic Formula Rank by ROIC |
1492
|
| Price | 47.85 |
| PBV / Sector |
5.96 / 2.65
|
| Earning Per Share | 0.97 |
| PE / Sector |
49.41 / 22.64
|
| PEG or PE/Growth / Sector |
-0.20 / 0.11
|
| Average 1M Daily Value |
28.25 M
GREAT
|
| Average 1W Daily Value |
29.28 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:15 |
| Symbol | KNSA |
| Name | KINIKSA PHARMACEUTICALS LTD |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 46.30 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,609.93 / 9,480.84 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 105 Piccadilly, London, United Kingdom, W1J 7NJ
Phone: 44 78 1431 9100
Website: https://www.kiniksa.com
Employees: 366
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
